SLXNW · Silexion Therapeutics Corp · Suppliers & Customers
$0.00
+0.00 (+0.00%)
At close · Nov 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2026, we had cash and cash equivalents of $4.8 million. Based on our current cash balance, as well as our history of operating losses and negative cash flows from operations, combined with our anticipated use of cash to, among other things, (i) fund the clinical development of SIL204, (ii) identify and develop new product candidates, and (iii) seek approval for SIL204 and any other product candidates we may develop, our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the issuance date of our consolidated financial statements for the three-month and nine-month periods ended September 30, 2026 included in this quarterly report, but rather, for only several months from the filing date of this quarterly report, under our current business plan, as a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
Market Cap
$974,292
Shares
649,528
Volume · Nov 19
300
Avg daily vol (3M)
39.06K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Supply Chain
Customers, suppliers, competitors and partners, private companies included: the ones SLXNW names, and the companies that name SLXNW.
Read supply chains in your AI or your code through MCP and the API →
Pro
See who SLXNW sells to, buys from and competes with
- 0 suppliers
- 0 customers
- 42 competitors
Pro names each company, links it to its own page, shows any revenue share the filing states, and quotes the sentence it comes from.
Key facts
CIK
2022416
CUSIP
G1281K148
13F (30d)
27 filings
21 filers
Visit website
Investor relations